What Researchers Did
The researchers looked back at records of 88 patients treated for sudden hearing loss with no clear cause between 2008 and 2013, and compared vasodilator infusion treatment combined with hyperbaric oxygen (HBO₂) therapy against vasodilator infusion treatment alone.
What They Found
In this retrospective study of 88 patients with idiopathic sensorineural hearing loss, a therapeutic effect was found with both treatments, 55% with HBO₂ therapy and 65% without it, and the difference between the two methods was not statistically significant. The effect within each treatment group was reported with p less than 0.0001. The best effect of treatment was seen in patients with apicocochlear hearing impairment. Patient age had no statistically significant relevance. Relief of tinnitus was seen mainly in patients with apicocochlear hearing loss.
What This Means for Canadian Patients
For people with sudden hearing loss of unknown cause, this abstract reports that adding HBO₂ to vasodilator infusion therapy did not show a statistically significant difference from vasodilator infusion alone. The percentages were 55% with HBO₂ and 65% without. The abstract does not give HBO₂ pressures or session numbers, so it cannot guide a specific treatment plan. Patients should talk with their own doctor about their options.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This was a retrospective study that was not randomised, so the two groups may have differed in ways the abstract does not describe, and the abstract does not show that either treatment caused the hearing gains.